See more : Zoomability Int AB (ZOOM.ST) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunityBio, Inc. (IBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunityBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Bankers Investment Trust PLC (BIT.NZ) Income Statement Analysis – Financial Results
- Global Offshore Services Limited (GLOBOFFS.NS) Income Statement Analysis – Financial Results
- Dong Ah Tire & Rubber Co.,Ltd (282690.KS) Income Statement Analysis – Financial Results
- GoHealth, Inc. (GOCO) Income Statement Analysis – Financial Results
- Waste Connections, Inc. (WCN.TO) Income Statement Analysis – Financial Results
ImmunityBio, Inc. (IBRX)
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00K | 240.00K | 934.00K | 605.00K | 2.20M | 47.00K | 45.00K | 44.00K | 236.00K | 641.00K | 600.00K |
| Cost of Revenue | 0.00 | 24.19M | 0.00 | 9.15M | 9.01M | -3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 253.00K |
| Gross Profit | 622.00K | -23.95M | 934.00K | -8.54M | -6.81M | 3.16M | 45.00K | 44.00K | 236.00K | 641.00K | 347.00K |
| Gross Profit Ratio | 100.00% | -9,980.00% | 100.00% | -1,411.90% | -309.26% | 6,717.02% | 100.00% | 100.00% | 100.00% | 100.00% | 57.83% |
| Research & Development | 232.37M | 248.15M | 195.96M | 139.51M | 112.00M | 53.42M | 39.78M | 26.55M | 11.43M | 1.60M | 446.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.39M | 57.12M | 95.39M | 227.68M | 4.33M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.07M | -3.30M | -1.00M | -1.47M | 0.00 | 0.00 |
| SG&A | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Other Expenses | 886.00K | -736.00K | 193.00K | 1.49M | -534.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 88.88M | 93.60M | 120.94M | 237.64M | 5.92M | 2.87M |
| Cost & Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Interest Income | 863.00K | 2.71M | 836.00K | 1.73M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K |
| Interest Expense | 129.20M | 63.52M | 14.85M | 9.07M | 5.92M | 433.00K | 618.00K | 66.00K | 0.00 | 0.00 | 463.00K |
| Depreciation & Amortization | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.56M | 5.57M | 3.61M | 1.47M | 128.00K | 4.00K |
| EBITDA | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| EBITDA Ratio | -70,125.72% | -143,324.17% | -33,865.52% | -32,252.56% | -6,356.77% | -189,008.51% | -207,897.78% | -274,756.82% | -100,594.92% | -949.14% | -263.17% |
| Operating Income | -362.25M | -351.30M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.50M | -238.88M | -6.21M | -2.27M |
| Operating Income Ratio | -58,239.55% | -146,374.17% | -35,361.88% | -36,509.09% | -7,095.87% | -209,338.30% | -220,266.67% | -282,954.55% | -101,218.64% | -969.11% | -378.17% |
| Total Other Income/Expenses | -221.64M | -65.99M | -19.56M | -25.36M | -3.95M | 1.66M | 2.20M | 3.12M | 1.70M | -609.00K | 223.00K |
| Income Before Tax | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Income Before Tax Ratio | -93,873.31% | -173,869.17% | -37,456.00% | -37,360.83% | -7,278.07% | -205,806.38% | -215,368.89% | -275,865.91% | -100,498.73% | -969.11% | -341.00% |
| Income Tax Expense | -40.00K | 34.00K | 9.00K | -1.85M | -105.00K | -503.00K | -493.00K | -572.00K | -301.00K | 1.00K | 1.00K |
| Net Income | -583.20M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Net Income Ratio | -93,761.41% | -173,883.33% | -37,456.96% | -37,055.70% | -7,273.30% | -204,736.17% | -214,273.33% | -274,565.91% | -100,371.19% | -969.27% | -341.17% |
| EPS | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| Weighted Avg Shares Out | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Weighted Avg Shares Out (Dil) | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
A short-squeeze stocks to buy are something investors need to watch out for. If investors believe that a stock's price will fall within a certain time frame, they will enter a short position.
These 5 stocks are potential short-squeeze candidates
In recent weeks, extreme volatility in specific stocks has resurged following the return of popular trader Keith Gill, also known as Roaring Kitty, to social media. After a nearly four-year hiatus, Gill disclosed a sizable stake in GameStop (NYSE: GME),...
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and...
ImmunityBio: Anktiva's Launch Demands A Reassessment
ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient...
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company's recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma...
The 3 Best Bargain Stocks to Buy in May 2024
There are several types of bargain stocks available to buy in the stock market. There are, of course, traditional bargain stocks with very low valuations and an average growth rate.
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA (nogapendekin alfa inbakicept-pmln). Coupled with...
Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells
You'll get no argument from me that GameStop (NYSE: GME ) is one of the best meme stocks to sell. However, the video game retailer has been around a long time, suggesting it's not the worst of the meme stocks...
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
CULVER CITY, Calif.--(BUSINESS WIRE)--The Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination...
What's going on with the ImmunityBio (IBRX) stock price?
ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug. It has risen for two straight days and is now sitting at its highest level since September 2021.
Source: https://incomestatements.info
Category: Stock Reports